FULL DETAILS (Read-only)  -> Click Here to Create PDF for Current Dataset of Trial
CTRI Number  CTRI/2023/09/057669 [Registered on: 15/09/2023] Trial Registered Prospectively
Last Modified On: 14/09/2023
Post Graduate Thesis  Yes 
Type of Trial  Observational 
Type of Study   Cross Sectional Study 
Study Design  Single Arm Study 
Public Title of Study   Antibiotic use audit among pediatric inpatients 
Scientific Title of Study   A Cross-Sectional Observational Study to Assess Prescription Pattern, Awareness of Parents regarding Disease and Use of Antimicrobial agents and Cost of treatment in Children Admitted in a Tertiary Care Hospital. 
Trial Acronym  NIL 
Secondary IDs if Any  
Secondary ID  Identifier 
NIL  NIL 
 
Details of Principal Investigator or overall Trial Coordinator (multi-center study)  
Name  Dr Padmaja Marathe 
Designation  Professor Additional 
Affiliation  Seth G.S. Medical College and K.E.M. Hospital 
Address  Department of Pharmacology and Therapeutics, Seth G.S. Medical College and K.E.M. Hospital, Parel, Mumbai.

Mumbai
MAHARASHTRA
400012
India 
Phone  9619466099  
Fax    
Email  pam2671@gmail.com  
 
Details of Contact Person
Scientific Query
 
Name  Dr Jagriti Jha 
Designation  Junior Resident 
Affiliation  Seth G.S. Medical College and K.E.M. Hospital 
Address  Department of Pharmacology and Therapeutics, Seth G.S. Medical College and K.E.M. Hospital, Parel, Mumbai.
NIL
Mumbai
MAHARASHTRA
400012
India 
Phone  7990081279  
Fax    
Email  jagritipjha@gmail.com  
 
Details of Contact Person
Public Query
 
Name  Dr Jagriti Jha 
Designation  Junior Resident 
Affiliation  Seth G.S. Medical College and K.E.M. Hospital 
Address  Department of Pharmacology and Therapeutics, Seth G.S. Medical College and K.E.M. Hospital, Parel, Mumbai.
NIL

MAHARASHTRA
400012
India 
Phone  7990081279  
Fax    
Email  jagritipjha@gmail.com  
 
Source of Monetary or Material Support  
Others(Self-support) 
 
Primary Sponsor  
Name  Dr Padmaja Marathe 
Address  Department of Pharmacology and Therapeutics, Seth G.S. Medical College and K.E.M. Hospital, Parel, Mumbai. 
Type of Sponsor  Other [Self] 
 
Details of Secondary Sponsor  
Name  Address 
Dr Jagriti Jha  Department of Pharmacology and Therapeutics, Seth G.S. Medical College and K.E.M. Hospital, Parel, Mumbai. 
 
Countries of Recruitment     India  
Sites of Study  
No of Sites = 1  
Name of Principal Investigator  Name of Site  Site Address  Phone/Fax/Email 
Dr Jagriti Jha  K.E.M. Hospital  Department of Pediatrics, Seth G.S. Medical College and K.E.M. Hospital, Parel, Mumbai.
Mumbai
MAHARASHTRA 
7990081279

jagritipjha@gmail.com 
 
Details of Ethics Committee  
No of Ethics Committees= 1  
Name of Committee  Approval Status 
Institutional Ethics Committee (IEC)-II  Approved 
 
Regulatory Clearance Status from DCGI  
Status 
Not Applicable 
 
Health Condition / Problems Studied  
Health Type  Condition 
Patients  (1) ICD-10 Condition: A00-B99||Certain infectious and parasitic diseases,  
 
Intervention / Comparator Agent  
Type  Name  Details 
Intervention  NIL  NIL 
Comparator Agent  NIL  NIL 
 
Inclusion Criteria  
Age From  1.00 Month(s)
Age To  12.00 Year(s)
Gender  Both 
Details  1. Children hospitalized to the Pediatrics ward.
2. Prescribed at least one antibiotic during their hospital stay.
3. Age more than 1 month and less than or equal to 12 years.
 
 
ExclusionCriteria 
Details  1. Children admitted to the pediatric ICU.
2. Legally Authorised Representative or children not willing to give informed consent or assent respectively.

 
 
Method of Generating Random Sequence   Not Applicable 
Method of Concealment   Not Applicable 
Blinding/Masking   Not Applicable 
Primary Outcome  
Outcome  TimePoints 
Prescription pattern of use of antimicrobial agents in pediatric inpatients  To be assessed at Single time point at the time of discharge of hospitalized pediatric patients 
 
Secondary Outcome  
Outcome  TimePoints 
Percentage awareness of parents per item (from the questionnaire)
Direct cost occurring that will include
Medical cost: Drugs, Laboratory investigations, other interventions (if any)
Non-medical cost: Travel, Food, Stay
Indirect cost occurring in the form of loss of wages of the guardian
Treatment outcome:
Time taken for clinical signs & symptoms of infection (including fever, cough, etc) to subside after starting antibiotic therapy
Number of days of hospitalisation
Number of children who responded to empirical antibiotic treatment
Number of children who required change of antibiotics
Number of children cured following change of antibiotic treatment
 
To be assessed at one time point that is on the day of discharge of hospitalized pediatric patients. 
 
Target Sample Size   Total Sample Size="378"
Sample Size from India="378" 
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" 
Phase of Trial   N/A 
Date of First Enrollment (India)   22/09/2023 
Date of Study Completion (India) Applicable only for Completed/Terminated trials 
Date of First Enrollment (Global)  Date Missing 
Date of Study Completion (Global) Applicable only for Completed/Terminated trials 
Estimated Duration of Trial   Years="1"
Months="3"
Days="0" 
Recruitment Status of Trial (Global)   Not Applicable 
Recruitment Status of Trial (India)  Not Yet Recruiting 
Publication Details   N/A 
Individual Participant Data (IPD) Sharing Statement

Will individual participant data (IPD) be shared publicly (including data dictionaries)?  

Response - NO
Brief Summary  

Infectious diseases contribute immensely to the global burden of disease that impacts public health systems and economies especially affecting children. In 2013, infectious diseases resulted in over 45 million years lost due to disability and over 9 million deaths. According to UNICEF, pneumonia, diarrhea and malaria were responsible for approximately 30 per cent of global deaths among children under the age of 5 in 2019. In India, infectious diseases account for 58% of all deaths among children aged 5 to 14 years.

Even among neonates, the frequency of infectious diseases, such as typhoid, diarrhea, measles, tuberculosis, and jaundice, remains the primary cause of infant morbidity and mortality in India. Hasan et al reported that around 3.69 lacs children aged below five years die every year from acute respiratory infections in India, accounting for 13-16% of all child deaths. Pneumonia and diarrhea remain the leading causes of mortality in India among children, causing about 2 lacs under five mortalities.

 

Antibiotics are among the most commonly administered medications in children. In ambulatory settings in the USA, antibiotics are prescribed during as many as one in five pediatric visits. Cross-sectional point prevalence studies have shown that more than 35% and 40% of hospitalized children are receiving antimicrobials at any given time in European and non-European countries, respectively. There are Indian studies done on off-label use of drugs in children which show that antibiotics are the most common off-label prescribed drugs (10 to 70%). Chauthankar et al. showed that in NICU, of all the drugs prescribed, antibiotics were the most common off-label prescription drugs (69.6%). Saiyed et al. states that almost 70% of the antibiotics prescribed in hospitalized children are off-label.   

An Indian study showed that use of antibiotics in PICU is up to 45%. While another study showed that in a PICU of tertiary care hospital, of all of the patients admitted 43% received antibiotics prophylactically, 42% empirically, and 15% therapeutically.

There are few studies documenting prescription pattern of antibiotics in hospitalized children in India. However, the studies have not looked at drug consumption pattern of antibiotics in hospitalized children.

 

The reason for increased off-label use of drugs being more prevalent in children is a smaller number of pediatric clinical trials. Both economic and ethical factors can discourage pharmaceutical companies from conducting trials on children which results in potential delay in the authorization of antibiotics for children. Moreover, given the scarcity of information of new drugs including antibiotics  in children, data on drug safety and tolerability are often extrapolated from adult studies, with the consequent risks of underestimating toxicity, inadequate dosages and clinical failures.

 

Defined daily dose (DDD) as defined by WHO is the assumed average maintenance dose per day for a drug used for its main indication in adults. Prescribed daily dose (PDD) as per WHO is the dose actually prescribed by a physician for an individual person. The ratio of PDD to DDD is a useful metric to measure drug consumption in a defined population and it is a valuable WHO indicator in drug utilization studies. These indicators can only be used in adult population as per WHO. Pediatric DDDs are challenging to assign because of the variability in children’s doses as per the age and body weight.

Child Defined Daily Dose (cDDD), Child Drug Utilization index (cDUI), PDD/cDDD ratio indicators have been derived based on adult DDD and were used in a study by Hu et al. from pediatric patients.

   

There is no Indian study reporting evaluation of prescription pattern of antibiotics in pediatric population in terms of WHO indicators, PDD/cDDD ratio and using cDDD and cDUI.

 

Due to higher number of infectious diseases in developing countries like India especially in children, the use of antibiotics is widespread. Because of lack of stringent regulations in India and other developing countries, it is not difficult to obtain over the counter antibiotics and hence, antibiotics misuse is common. It has been observed that although parents are concerned about the use of over-the-counter antibiotics, they still demand it for faster relief. In earlier studies assessing parents’ awareness regarding antibiotics, 42.6% declared that antibiotics act against both viruses and bacteria, 55.9% believed antibiotics are required to treat fever, 50% didn’t know the consequences of antibiotics misuse, 58.4% believed that a doctor’s prescription is not required every time to administer antibiotics and 66.7% trusted the pharmacist in the antibiotic prescription. In an Indian study to find out level of awareness among parents, it was found that there were misconceptions about which diseases require antibiotics and the concept of antibiotic overuse leading to resistance was not known. Majority of them believed antibiotics are required every time the child falls sick. Misinformation and confusion was more among mothers and those with lower formal education.

 

Therefore, the need was felt to understand parents’ knowledge, attitude and practice regarding the disease condition which the child is suffering from and use of antibiotics for infectious diseases in their children.

 

Antimicrobials contributed around 16.8% of the of the total medicine sales worth USD 12.6 billion in India between 2013 and 2014. According to National Sample Survey Organization (NSSO) data on Key Indicators of Social Consumption in India: Health, (2017–18), the monthly per patient Out of Pocket (OOP) expenditure on infectious diseases by infection-affected populations is INR 881.56 and INR 1,156.34 in inpatient and outpatient care in India. One cost analysis study in pediatric population showed that average cost of management of pneumonia in children is 12245 ± 593 ($187.34 ± 9.07). About 58% of India’s health expenditure is done out of pocket of the patient. In spite of public health system and availability of generic drugs, the financial burden of infectious diseases in India is substantial owing to various factors.  However, there are no cost analysis Indian studies for antibiotics used for different types of infections. It is important to know how much financial burden is faced by parents when children are admitted with infections and whether they get the required antimicrobial agents from the hospital formulary.

 

The infections in children require prompt use of antimicrobial agents. It is necessary to find out the clinical outcome of antibiotic treatment in children as febrile period and number of hospitalization days largely depend on response to treatment. Unlike most children getting cured in developed nations, infectious diseases leading to morbidity and mortality has been reported to be higher in Indian patients.  There are very few global studies that has recorded response to treatment with antibiotics in children while there are no Indian studies assessing this aspect.

 

Hence it was of interest to evaluate prescription pattern, awareness of parents regarding use of antibiotics, cost analysis and clinical outcome of treatment of infectious diseases.

 

 

Primary Objective:

1.      To analyze the prescription pattern of antibiotics in hospitalized children using WHO drug use indicators and derived pediatric indicators.

Secondary Objectives:

1.      To find out awareness of parents of children regarding disease and use of antibiotics.

2.      To analyze cost of treatment during the hospital stay

3.      To assess the clinical outcome of treatment of infection.

 

Methodology:

Study Design- An Observational, cross- sectional, single-center, Questionnaire based Study

Study Site- In-Patient ward of Department of Pediatrics of a Tertiary Care Hospital.

Study duration - The total duration of the study will be of 15 months, of which data will be collected over a period of 12 months and analyzed over a period of 3 months.

Sampling method- Convenient sampling till the required sample size is achieved.

Study Population: The study population will include all admitted children receiving antibiotics in one unit of the Pediatrics department.

Duration of study participation: The study involves a single interview with every parent at the end of hospital stay and hence the duration of participation equals the duration of the interview, which is expected to be 30 minutes for the parents.

 

Sample Size Calculation:

The expected frequency of use of antibiotics in pediatric population is 67%.(28) With confidence level of 95%, keeping margin of error as 5%, a non-response rate of 10%(29), the sample size can be calculated as follows:

n = z^2 * p * q / e^2

where:

  • z = the z-value for the desired confidence level (1.96 for a 95% confidence level)
  • p = the expected frequency of antibiotic use (0.67)
  • q = 1 - p (0.33)
  • e = the desired level of precision (0.05)

n = (1.96) ^2 * 0.67 * 0.33* / (0.05)^2

n = 340

Therefore, the sample size required for the study is 340 patients. However, to account for the non-response rate of 10%, we will have to recruit additional 38 patients as follows.

(N’=N/(1-d))

d = non-response rate

Therefore, N’=340/ (1-0.1) = 340/0.9 = 378

 

Ethical considerations and informed consent:

This study will be conducted in compliance with the protocol, the IEC, and Indian GCP guidelines and national ICMR guidelines on biomedical health research. During the study, any amendment or modification to the protocol will be submitted to IEC.

The study will begin after approval from Institutional Ethics Committee. Children who are being admitted to the ward for treatment of infection and fulfilling the inclusion-exclusion criteria will be enrolled in the study.

Written informed consent will be taken from LAR and impartial witness (when applicable) and verbal assent will be taken in children aged 7-12 years in addition to parent/ LAR consent.

 
Close